Bezlotoxumab for Recurrent Clostridium difficile Infection: Is It Worth It?

Researchers assessed the probable cost-effectiveness of adding a humanized monoclonal antibody to standard therapy to prevent CDI recurrence.

Approximately 25% of all instances of symptomatic Clostridium difficile infection (CDI) recur within 30 days, and the attributable cost of a recurrence is more than $11,000. Bezlotoxumab is a humanized monoclonal antibody directed against C. difficile toxin B. Two prior randomized studies, MODIFY I and II, demonstrated a 38% reduced risk for recurrent CDI when bezlotoxumab is given with standard antimicrobial therapy. These researchers conducted the current industry-supported study to assess the cost-effectiveness of bezlotoxumab versus placebo for prevention of recurrent CDI.

A computer-based Markov health state transition model simulated the natural history of recurrent CDI in the population in the intention-to-treat arm of the MODIFY I/II…

Reviewing Author

Neil M. Ampel, MD

Disclosures

Editorial BoardsUpToDate

Leadership Positions in Professional SocietiesCoccidioidomycosis Study Group (Past President, Secretary, Treasurer)

Neil M. Ampel, MD

Disclosures

Editorial BoardsUpToDate

Leadership Positions in Professional SocietiesCoccidioidomycosis Study Group (Past President, Secretary, Treasurer)

Bezlotoxumab for Recurrent Clostridium difficile Infection: Is It Worth It?

Topics

Reviewing Author